These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Added value of gastrin receptor scintigraphy in comparison to somatostatin receptor scintigraphy in patients with carcinoids and other neuroendocrine tumours. Gotthardt M; Béhé MP; Grass J; Bauhofer A; Rinke A; Schipper ML; Kalinowski M; Arnold R; Oyen WJ; Behr TM Endocr Relat Cancer; 2006 Dec; 13(4):1203-11. PubMed ID: 17158765 [TBL] [Abstract][Full Text] [Related]
29. Radiolabeled somatostatin analog scintigraphy in oncology and immune diseases: an overview. Kwekkeboom DJ; Krenning EP Eur Radiol; 1997; 7(7):1103-9. PubMed ID: 9265684 [TBL] [Abstract][Full Text] [Related]
30. In vivo detection of malignant thymic masses by indium-111-DTPA-D-Phe1-octreotide scintigraphy. Lastoria S; Vergara E; Palmieri G; Acampa W; Varrella P; Caracò C; Bianco RA; Muto P; Salvatore M J Nucl Med; 1998 Apr; 39(4):634-9. PubMed ID: 9544670 [TBL] [Abstract][Full Text] [Related]
31. Intraoperative tumour detection using 111In-DTPA-D-Phe1-octreotide and a scintillation detector. Benjegård SA; Forssell-Aronsson E; Wängberg B; Skånberg J; Nilsson O; Ahlman H Eur J Nucl Med; 2001 Oct; 28(10):1456-62. PubMed ID: 11685487 [TBL] [Abstract][Full Text] [Related]
32. Indium-111-DTPA-D-Phe-1-octreotide and technetium-99m-(V)-dimercaptosuccinic acid scanning in the preoperative staging of medullary thyroid carcinoma. Kurtaran A; Scheuba C; Kaserer K; Schima W; Czerny C; Angelberger P; Niederle B; Virgolini I J Nucl Med; 1998 Nov; 39(11):1907-9. PubMed ID: 9829581 [TBL] [Abstract][Full Text] [Related]
33. The therapeutic value of SST-A octreotide alone or with adjuvant treatment in patients with advanced medullary thyroid carcinoma and positive (111)In-octreotide scan. Vainas I; Drimonitis A; Boudina M; Kaprara A; Iakovou I; Salem N; Koussis C Hell J Nucl Med; 2005; 8(1):43-7. PubMed ID: 15886753 [TBL] [Abstract][Full Text] [Related]
34. [111In-pentetreotide in the study of tumors expressing somatostatin receptors]. Mateos Fernández J; Pons Pons F; Fuster Pelfort D; Vidal-Sicart S; Lomeña Caballero F; Herranz García-Romero R Rev Esp Med Nucl; 1999 Oct; 18(5):325-30. PubMed ID: 10562660 [TBL] [Abstract][Full Text] [Related]
36. [Role of somatostatin analogs in the treatment of neuroendocrine tumours]. Cuccurullo V; Cascini GL; Rambaldi PF; Mansi L Minerva Endocrinol; 2001 Sep; 26(3):135-43. PubMed ID: 11753236 [TBL] [Abstract][Full Text] [Related]
37. In vitro and in vivo studies of three radiolabelled somatostatin analogues: 123I-octreotide (OCT), 123I-Tyr-3-OCT and 111In-DTPA-D-Phe-1-OCT. Virgolini I; Angelberger P; Li S; Yang Q; Kurtaran A; Raderer M; Neuhold N; Kaserer K; Leimer M; Peck-Radosavljevic M; Scheithauer W; Niederle B; Eichler HG; Valent P Eur J Nucl Med; 1996 Oct; 23(10):1388-99. PubMed ID: 8781146 [TBL] [Abstract][Full Text] [Related]
38. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Krenning EP; Kwekkeboom DJ; Bakker WH; Breeman WA; Kooij PP; Oei HY; van Hagen M; Postema PT; de Jong M; Reubi JC Eur J Nucl Med; 1993 Aug; 20(8):716-31. PubMed ID: 8404961 [TBL] [Abstract][Full Text] [Related]
39. Use of somatostatin analogue scintigraphy in the localization of recurrent medullary thyroid carcinoma. Bernà L; Chico A; Matías-Guiu X; Mato E; Catafau A; Alonso C; Mora J; Mauricio D; Rodríguez-Espinosa J; Marí C; Flotats A; Martín JC; Estorch M; Carrió I Eur J Nucl Med; 1998 Nov; 25(11):1482-8. PubMed ID: 9799343 [TBL] [Abstract][Full Text] [Related]
40. Combined use of 111In-DTPA-D-Phe-1-octreotide (OCT) and 123I-vasoactive intestinal peptide (VIP) in the localization diagnosis of medullary thyroid carcinoma (MTC). Kurtaran A; Leimer M; Kaserer K; Yang Q; Angelberger P; Niederle B; Virgolini I Nucl Med Biol; 1996 May; 23(4):503-7. PubMed ID: 8832707 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]